Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Varenicline safety update

The Medicines and Healthcare products Regulatory Agency has announced an update to the product information for varenicline (Champix®) highlighting concerns over suicidal thoughts and behaviour.

Following a European review in conjunction with the European Medicines Agency (EMEA) it has been recommended that:

  • Clinicians should already be aware of the risk of using varenicline in patients who have an underlying mental illness
  • Clinicians should advise patients who are trying to stop smoking that they can develop symptoms of depression
  • Patients who develop suicidal thoughts while taking varenicline should stop their treatment and contact their doctor immediately

Action: Clinicians should avoid using varenicline in patients with underlying mental illness. Patients who are prescribed varenicline should be advised as recommended above.

Share 'Varenicline safety update' on Email Share 'Varenicline safety update' on Delicious Share 'Varenicline safety update' on Digg Share 'Varenicline safety update' on Facebook Share 'Varenicline safety update' on Google+ Share 'Varenicline safety update' on reddit Share 'Varenicline safety update' on StumbleUpon Share 'Varenicline safety update' on Twitter

atomic-wealth

No Comments to “Varenicline safety update”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,527 spam comments.

atomic-wealth
fond-illness
summer